Pharmacokinetic-pharmacodynamic modeling of metformin for the treatment of type II diabetes mellitus

Open Biomedical Engineering Journal

Volumn 5, Issue 1, 2011, Pages 1-7

  Sun, Lin ^a,b   Kwok, Ezra ^a   Gopaluni, Bhushan ^a   Vahidi, Omid ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CHINA UNIVERSITY OF PETROLEUM   (China)

Author keywords

Insulin; Metformin; Modeling; Pharmacodynamic; Pharmacokinetic; Type II diabetes mellitus

Indexed keywords

ANTIHYPERGLYCEMIC AGENT; CLINICAL DATA; COMBINATION TREATMENTS; DIABETES MELLITUS; DIABETIC PATIENT; HUMAN BODIES; INSULIN INFUSIONS; METFORMINS; MODEL PARAMETERS; MONO-THERAPY; ORAL ADMINISTRATION; PHARMACOLOGICAL AGENTS; TYPE II;

COMPUTER SIMULATION; INSULIN; MODELS; PHARMACODYNAMICS;

PHARMACOKINETICS;

INSULIN; METFORMIN;

ARTICLE; COMBINATION CHEMOTHERAPY; COMPARTMENT MODEL; DIABETIC PATIENT; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG USE; HUMAN; INSULIN INFUSION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; SINGLE DRUG DOSE;

EID: 80053533362     PISSN: None     EISSN: 18741207     Source Type: Journal    
DOI: 10.2174/1874120701105010001     Document Type: Article

References (24)

1. V. W. Bolie, "Coeffcients of normal blood glucose regulation, " J. Appl. Physiol., vol. 16, no. 5, pp. 783, 1961.
2. J. T. Sorensen, "A physiological model of glucose metabolism in man and its use to design and assess improved insulin therapies for diabetes, " In PhD thesis, Massachusetts Institute of Technology, 1985.
3. C. Cobelli, and A. Mari, "Validation of mathematical models of complex endocrinemetabolic systems. A case study on a model of glucose regulation, " Med. Biol. Eng. Comput., vol. 21, no. 4, pp. 390-399, 1983.
4. M. S. Ibbini, M. A. Masadeh, and M. M. Bani Amer, "A semiclosed-loop optimal control system for blood glucose level in diabetics, " J. Med. Eng. Technol., vol. 28, no. 5, pp. 189-196, 2004.
5. M. S. Ibbini, and M. A. Masadeh, "A fuzzy logic based closed-loop control system for blood glucose level regulation in diabetics, " J. Med. Eng. Technol., vol. 29, no. 2, pp. 64-69, 2005.
6. O. Vahidi, K. E. Kwok, R. B. Gopaluni, and L. Sun, "Development of a physiological model for patients with type 2 Diabetes mellitus, ": Proc. Am. Control Conf., Jun. 2010.
7. H. C. S. Howlett and C. J. Bailey, "A risk-benefit assessment of metformin in type 2 diabetes mellitus, " Drug Saf., vol. 20, no. 6, pp. 489-503, 1999.
8. E. M. Wildasin, D. J. Skaar, W. R. Kirchain, and M. Hulse, "Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus, " J. Pharmacother., vol. 17, no.1, pp. 62-73, 1997.
9. K. Johansen, "Efficacy of metformin in the treatment of NIDDM, " Meta-analysis. Diabetes care, vol. 22, no. 1, pp. 33, 1999.
10. M. Danhof, E. C. M. de Lange, O. E. Della Pasqua, B. A. Ploeger, and R. A. Voskuyl, "Mechanism-based pharmacokineticpharmacodynamic (PK-PD) modeling in translational drug research, " Trends Pharmacol. Sci., vol. 29, no. 4, pp. 186-191, 2008.
11. D. Z. D'argenio, and A. Schumitzky, "A program package for simulation and parameter estimation in pharmacokinetic systems, " Comput. Methods Programs Biomed., vol. 9, no. 2, pp. 115, 1979.
12. D. Stepensky, M. Friedman, W. Srour, I. Raz, and A. Homan, "Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation, " J. Control Release, vol. 71, no. 1, pp. 107-115, 2001.
13. P. J. Pentikainen, P. J. Neuvonen, and A. Penttila, "Pharmacokinetics of metformin after intravenous and oral administration to man, " Eur. J. Clin. Pharmacol., vol. 16, no. 3, pp. 195-202, 1979.
14. S. H. Lee, and K. Kwon, "Pharmacokinetic-pharmacodynamic modeling for the relationship between glucose-lowering effect and plasma concentration of metformin in volunteers, " Arch. Pharm. Res., vol. 27, no. 7, pp. 806-810, 2004.
15. L. S. Hermann, A. Melander, et al., "Biguanides: basic aspects and clinical uses, " International textbook of diabetes mellitus, 1992.
16. K. Cusi, and R. A. DeFronzo, "Metformin: a review of its metabolic effects, " Diabetes Rev., vol. 6, no. 2, pp. 89-131, 1998.
17. J. Kuhlmann, W. Puls, and H. J. Ahr, "Oral antidiabetics, " Springer, 1996.
18. L. Pala, E. Mannucci, I. Dicembrini, and C. M. Rotella, "A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients, " Diabetes Res. Clin. Pract., vol. 78, no. 1, pp. 132-135, 2007.
19. D. Stepensky, M. Friedman, I. Raz, and A. Hoffman, "Pharmacokinetic pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect, " Drug Metab. Dispos., vol. 30, no. 8, pp. 861, 2002.
20. C. Wilcock, and C. J. Bailey, "Reconsideration of inhibitory effect of metformin on intestinal glucose absorption, " J. Pharm. Pharmacol., vol. 43, no. 2, pp. 120, 1991.
21. M. P. Christiansen, and M. K. Hellerstein, "Effects of metformin on hepatic glucose metabolism. Current Opinion in Endocrinology, " Diabetes Obes., vol. 5, no. 4, pp. 252, 1998.
22. C. J. Bailey and R. C. Turner, "Metformin, " N. Engl. J. Med., vol. 334, no. 9, pp. 574, 1996.
23. A. H. Moreno, A. R. Burchell, L. M. Rousselot, W. F. Panke, S. F. Slafsky, and J. H. Burke. "Portal blood flow in cirrhosis of the liver, " J. Clin. Invest., vol. 46, no. 3, pp. 436-445, 1967.
24. E. D. Lehmann, and T. Deutsch, "A physiological model of glucose insulin interaction in type I diabetes mellitus, " J. Biomed. Eng., vol. 14, pp. 235-242, 1992.